The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Self-citationTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Self-citationGershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Self-citationWoo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Self-citationHodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,321
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Self-citationPrognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Self-citationDummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 987
McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Self-citationHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Self-citationPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Self-citationKIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Self-citationHodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Self-citationLeiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 688
Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx176 · Cited by 671
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Self-citationEggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
Self-citationHodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Gonzalez, R., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 608
Wang, C., Thudium, K. B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 601
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30497-2 · Cited by 588
Kirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1103-3 · Cited by 552
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8023 · Cited by 516
Self-citationAtkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30231-0 · Cited by 509
Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30180-8 · Cited by 499
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6270 · Cited by 482
Self-citationMaio, M., Grob, J.-J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Chiarion-Sileni, V., Testori, A., Chen, T.-T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.6018 · Cited by 481
Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
Self-citationSchadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
Grob, J. J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., Souteyrand, P., Sassolas, B., Cesarini, J.-P., Lionnet, S., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)12445-x · Cited by 433
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4514 · Cited by 352
Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30126-7 · Cited by 334
Self-citationTarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Amaria, R. N., Prieto, P. A., Tetzlaff, M. T., Reuben, A., Andrews, M. C., Ross, M. I., Glitza, I. C., Cormier, J., Hwu, W.-J., Tawbi, H. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30015-9 · Cited by 299
Self-citationRibas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 299
Sznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M., Lebbé, C., Kirkwood, J. M., Schachter, J., Daniels, G. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1167 · Cited by 286
Self-citationEggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 285
Larkin, J., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Sileni, V. C., Gogas, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70051-8 · Cited by 278
Evaluation of dosing strategy for pembrolizumab for oncology indications
Freshwater, T., Kondic, A., Ahamadi, M., Li, C. H., de Greef, R., de Alwis, D., & Stone, J. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0242-5 · Cited by 267
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 262
Self-citationCascinelli, N., Belli, F., MacKie, R. M., Santinami, M., Bufalino, R., & Morabito, A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06068-8 · Cited by 250
Long, G. V., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 245
Self-citationZhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 244
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Agrawal, S., Feng, Y., Roy, A., Kollia, G., & Lestini, B. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0177-2 · Cited by 222
Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., Gonzalez, R., Kefford, R., Hamid, O., Schuchter, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1025 · Cited by 221
Self-citationJohnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 216
Self-citationMaio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30106-2 · Cited by 216
Self-citationLong, G. V., Tykodi, S. S., Schneider, J. G., Garbe, C., Gravis, G., Rashford, M., Agrawal, S., Grigoryeva, E., Bello, A., Roy, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy408 · Cited by 206
Delord, J.-P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2923 · Cited by 198
Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., Blank, C., Cranmer, L. D., Robert, C., Pavlick, A. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.022 · Cited by 187
Self-citationCallahan, M. K., Kluger, H., Postow, M. A., Segal, N. H., Lesokhin, A., Atkins, M. B., Kirkwood, J. M., Krishnan, S., Bhore, R., Horak, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2850 · Cited by 186
Schreuer, M., Jansen, Y., Planken, S., Chevolet, I., Seremet, T., Kruse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 184
Feng, Y., Roy, A., Masson, E., Chen, T.-T., Humphrey, R., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 183
Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., & Lebbé, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt161 · Cited by 176
Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J.-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1588 · Cited by 176
Ives, N. J., Suciu, S., Eggermont, A. M. M., Kirkwood, J., Lorigan, P., Markovic, S. N., Garbe, C., Wheatley, K., Bufalino, R., Cameron, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.006 · Cited by 174
Beaver, J. A., Hazarika, M., Mulkey, F., Mushti, S., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 171
Anker, C. J., Grossmann, K. F., Atkins, M. B., Suneja, G., Tarhini, A. A., & Kirkwood, J. M. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.01.038 · Cited by 162
Robert, C., Schadendorf, D., MESSINA, M. E., Hodi, F. S., & O'Day, S. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3080 · Cited by 156
Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu441 · Cited by 146
Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., Stadler, R., Weichenthal, M., Eigentler, T., Ellwanger, U., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn001 · Cited by 138
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
Bhatia, A., & Kumar, Y. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 137
Wolchok, J. D., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Schadendorf, D., de Pril, V., Heller, K. N., Chen, T., Ibrahim, R. A., et al. (2010) · PubMed · Cited by 135
Correction to Lancet Oncol 2015; 16: 522–30
Eggermont, A. M. M., Chiarion‐Sileni, V., & Grob, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70271-8 · Cited by 128
The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
Ekedahl, H., Cirenajwis, H., Harbst, K., Carneiro, A., Nielsen, K., Olsson, H. L., Lundgren, L., Ingvar, C., & Jonsson, G. G. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12504 · Cited by 125
Alva, A. S., Daniels, G. A., Wong, M. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G. P., Logan, T. F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1910-x · Cited by 115
Self-citationFlaherty, L. E., Othus, M. K. D., Atkins, M. B., Tuthill, R. J., Thompson, J. A., Vetto, J. T., Haluska, F. G., Pappo, A. S., Sosman, J. A., Redman, B. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1590 · Cited by 114
Self-citationAm, E., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R., et al. (2008) · Research Explorer (The University of Manchester) · Cited by 111
Carlino, M. S., Long, G. V., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C. U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.034 · Cited by 104
Hansson, J., Aamdal, S., Bastholt, L., Brandberg, Y., Hernberg, M., Nilsson, B. R., Stierner, U. K., & von der Maase, H. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70288-6 · Cited by 103
Dréno, B., Ribas, A., Larkin, J., Ascierto, P. A., Hauschild, A., Thomas, L., Grob, J., Koralek, D. O., Rooney, I. A., Hsu, J. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx040 · Cited by 101
Weber, J. S., Vecchio, M. D., Mandalà, M., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J., Chiarion‐Sileni, V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz255 · Cited by 98
Schadendorf, D., Dummer, R., Hauschild, A., Robert, C., Hamid, O., DAUD, A. I., van den Eertwegh, A. J. M., Cranmer, L. D., O'Day, S. J., Puzanov, I. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.018 · Cited by 97
Self-citationWang, X., Feng, Y.-Y., Bajaj, G., Gupta, M., Agrawal, S., Yang, A., Park, J.-S., Lestini, B. J., & Roy, A. K. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12133 · Cited by 91
Long, G. V., Schachter, J., Ribas, A., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9503 · Cited by 87
Eggermont, A. M. M., Suciu, S., Rutkowski, P. L., Kruit, W., Punt, C. J. A., Dummer, R., Salès, F., Keilholz, U., de Schaetzen, G., & Testori, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.014 · Cited by 86
Davar, D., Ding, F., Saul, M. I., Sander, C., Tarhini, A. A., Kirkwood, J. M., & Tawbi, H. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0279-5 · Cited by 76
Robert, C., Long, G. V., Schachter, J., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9504 · Cited by 68
Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Sondak, V. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9500 · Cited by 64
Self-citationAgarwala, S. S., Lee, S. J., Yip, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2951 · Cited by 51
de la Cruz‐Merino, L., Guardo, L. D., Grob, J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Ascierto, P. A., Evans, J., Gómez-Escobar, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1246-0 · Cited by 48
Chen, G., McQuade, J. L., Panka, D. J., Hudgens, C. W., Amin‐Mansour, A., Mu, X. J., Bahl, S., Jané‐Valbuena, J., Wani, K., Reuben, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0509 · Cited by 46
Hodi, F. S., Postow, M. A., Chesney, J. A., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9004 · Cited by 44
Self-citationBlank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.007 · Cited by 39
Retseck, J., VanderWeele, R. A., Lin, H., Lin, Y., Butterfield, L. H., & Tarhini, A. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0141-1 · Cited by 25
Puzanov, I. J., Dummer, R., Schachter, J., Pavlick, A. C., Gonzalez, R. C., Ascierto, P. A., Margolin, K. A., Hamid, O., Agarwala, S. S., Carlino, M. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3012 · Cited by 24
Pavlick, A. C., Ribas, A., Gonzalez, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9020 · Cited by 23
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Shreders, A. J., Joseph, R. W., Peng, C., Ye, F., Zhao, S., Puzanov, I. J., Sosman, J. A., & Johnson, D. B. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0281 · Cited by 21
Self-citationOlson, D. J., Luke, J. J., Hallmeyer, S., Bajaj, M., Carll, T. C., Krausz, T. N., Zha, Y., Karrison, T., Brockstein, B., Sondak, V. K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9514 · Cited by 20
Lebbé, C., Meyer, N., Mortier, L., Márquez‐Rodas, I., Robert, C., Rutkowski, P. L., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.057 · Cited by 9
Weber, J. S., Mandalà, M., Vecchio, M. D., Gogas, H. J., Arance, A. M., Cowey, L. C., Dalle, S., Schenker, M., Chiarion‐Sileni, V., Márquez‐Rodas, I., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.048 · Cited by 9
Cited by
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324
Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71788-z · Cited by 14
Metadata
- Authors
- Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., Freeman, M., Galan, A., Gastman, B., Guild, V., Johnson, D., Joseph, R. W., Lange, J. R., Nath, S., Olszanski, A. J., Ott, P., Gupta, A. P., Ross, M. I., Salama, A. K., Skitzki, J., Sosman, J., Swetter, S. M., Tanabe, K. K., Wuthrick, E., McMillian, N. R., & Engh, A. M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2019-04
- Volume
- 17
- Issue
- 4
- Pages
- 367-402
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2939676267
- Cited by
- 436
- References
- 150
- FWCI
- 29.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.